Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin

Diabetes

Volumn 45, Issue 12, 1996, Pages 1750-1754

  Fineberg, Naomi S ^a   Fineberg, S Edwin ^a,b   Anderson, James H ^a   Birkett, Martin A ^a   Gibson, Reid G ^a   Hufferd, Suzan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LYSYLPROLINE DERIVATIVE; PIG INSULIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029860260     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.12.1750     Document Type: Article

References (28)

1. Galloway JA: New directions in drug development (mixtures, analogues, and modeling). Diabetes Care 16 (Suppl. 3): 16-23, 1993
2. Binder C, Nielse A, Jorgensen K: The absorption of an acid and a neutral insulin solution after subcutaneous injection into different regions in diabetic patients. Scand Journal Clin Invest 19:156-163, 1967
3. Kang S, Brange J, Burch A, Volund A, Owens D: Subcutaneous insulin absorption explained by insulins' physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:942-948, 1991
4. Roy B, Chou MC, Field JB: Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 50:475-479, 1980
5. Gardner DF, Arakani RF, Podet EJ, Nell LJ, Thomas JW, Field JB: The pharmakokinetics of subcutaneous regular insulin in type 1 diabetic patients using a glucose clamp technique. J Clin Endocrinol Metab 63:689-694, 1986
6. Dimitriadis GD, Gerich JE: Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6:374-377, 1983
7. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P: Absorption kinetics and biological effects of subcutaneously injected insulin preparations. Diabetes Care 5:77-91, 1982
8. Woodworth JR, Howey DC, Bowsher RR: Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care 17:64-69, 1994
9. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
10. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys (B28), Pro (B29)] in IDDM. Diabetologia 37:713-720, 1994
11. Charbonnel B, Blanchard P: Insulin analogs. Diabetes Metab 20 (2 pt 2):194-205, 1994
12. Brange J: Design of insulin analogues for meal-related therapy. J Diabetes Complications 7:106-112, 1993
13. Slieker LJ, Brooke GS, Chance RE, Fan L, Hoffmann JA, Howey DC, Long HB, Mayer J, Shields JE, Sundell KL, DiMarchi RD: In Current Directions in Insulin-Like Growth Factor Research, LeRoith D, Raizaida MK, Eds. New York, Plenum Press, 1994
14. Francis AJ, Harming I, Alberti KGGM: The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia 28:330-334, 1985
15. Howey DC, Bowsher BR, Brunelle RL, Woodworth JR: [Lys (B28), Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
16. Bryant C, Strohl M, Green LK, Long HB, Alter LA, Pekar AH, Chance RE, Brems DN: Detection of an equilibrium intermediate in the folding of a monomeric analog. Biochemistry 31:5692-5698, 1992
17. Brems DN, Brown PL, Bryant C, Chance RE, Green LK, Long HB, Miller AA, Millican R, Shields JE, Frank BH: Altering the association properties of insulin by amino acid replacement. Protein Eng 5:527-533, 1992
18. Fineberg SE, Rathbun MJ, Hufferd S, Fineberg NS, Spradlin CT, Galloway JA, Frank B: Immunologic aspects of human proinsulin therapy. Diabetes 37:276-280, 1988
19. Winer BJ: Statistical Principles in Experimental Design. New York, McGraw Hill, 1971, p. 149-260
20. Mehta C, Patel N: StatXact-Turbo®, User Manual. Cambridge, MA, Cytel Software, 1992, p. 5-21-5-27
21. Milliken GA, Johnson DE: Analysis of Messy Data. Vol. 1. New York, Van Nostrand Reinhold, 1984, p. 352-360
22. Fineberg SE, Galloway JA, Fineberg NS, Goldman J: Effects of species of origin, purification levels and formulation in insulin immunogenicity. Diabetes 32:92-99, 1983
23. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S: Immunogenicity of recombinant DNA human insulin. Diabetologia 25:465-469, 1983
24. Fineberg SE, Fineberg NS, Galloway JA, Estridge T, Hufferd S: Sequellae of human vs pork insulins in type 1 and 2 diabetes in a 2 year double blind clinical trial (Abstract). Diabetes 37 (Suppl.):96, 24A, 1988
25. Fineberg NS, Fineberg SE, Mahler RJ, Linarelli LG: Is regular human insulin less immunogenic than repository (Abstract), Diabetes 35 (Suppl. 1):91A, 1986
26. DiMarchi RD, Chance RE, Long HB Shields JE, Slieker LJ: Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Hormone Res 41 (Suppl. 2):93-96, 1994
27. Ottesen JL, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D, Havelund S, Fogh JM: The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1195, 1994
28. Galloway JA, Fireman P, Fineberg SE: Complications of insulin therapy: a brief review of four years experience with human insulin (rDNA). In Diabetes Mellitus Achievements and Skepticism, Church J, Ed., Oxford U Press, Roy Soc Med Int Congress and Symposium Series 77:55-64, 1984